Financial

LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Phase 3 Completion

CINCINNATI–(BUSINESS WIRE)–LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of cardiovascular disease (CVD), today announced that the Board of Directors has appointed David Cory as Chief Executive Officer and a member of the Board of Directors, […]

Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System

IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announces that the U. S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the DETOUR System, an FDA-designated Breakthrough Device, […]

Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys

PARIS–(BUSINESS WIRE)– Gradient Denervation Technologies (“Gradient”), a medical device company developing an innovative catheter-based solution for the treatment of pulmonary hypertension, announces today the successful closing of a €14m Series A financing that will support ongoing clinical development and evaluation of the ultrasound-based catheter device. Asabys Partners led the round through its […]

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company), announced today that United Therapeutics Corporation (UTHR) filed a patent infringement action under the Hatch-Waxman Act in the U.S. District Court for the District of Delaware (District Court) asserting infringement of U.S. patent No. […]

Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices

SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective […]

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of August 31, 2023

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of August 31, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code […]

Cordis Names Scott Drake Executive Chairman

MIAMI LAKES, Fla., Sept. 5, 2023 /PRNewswire/ — Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced the appointment of Scott Drake as Executive Chairman of its Board of Directors. Drake, who joined the Cordis board in August of 2021, succeeds Duke Rohlen who served as Executive Chairman since […]